Introduction
Impulsive aggression (IA) is considered a maladaptive form of aggression that is reactive, overt, and occurring outside the acceptable social context. 1, 2 The presence of IA features in patients diagnosed with neuropsychiatric disorders such as attentiondeficit/hyperactivity disorder (ADHD) amplifies the risk of poor outcomes even when treatment of the primary disorder is optimized. 3 Many children and adolescents with ADHD display clinically significant aggression, with the predominant subtype being IA. 3 IA becomes clinically distinguishable once ADHD-targeted therapy is maintained. This has been demonstrated in the Multimodal Treatment Study of Children with ADHD, in which 54% of the children with ADHD presented with clinically significant aggression prior to 14 months of treatment (medication with or without behavioral therapy); however, despite treatment, 44% of these children with aggres-sion at baseline exhibited persistent IA. 1 Although there are guideline recommendations for adjunctive targeted therapy when IA persists with ADHD treatment, 1,4-6 the agents being used have not proven to be adequately effective and have tolerability issues; furthermore, there are limited data for clinicians due to the paucity of randomized clinical trials. 3 Currently, there is no US Food and Drug Administration (FDA)-approved medication specifically indicated to treat IA that may be observed in children with ADHD, and therefore there is a need for an effective medication with an improved tolerability profile. 3, 7 Although alterations in the central nervous system (CNS) biology have been implicated, the pathophysiology of IA is not fully understood. 1, 3 It has been hypothesized that IA is associated with the recruitment of the acute threat response system structures -the amygdala, hypothalamus, and periaqueductal gray. 8 The recruitment of these structures in order to initiate IA may reflect the functioning of the ventromedial prefrontal cortex, the dorsomedial prefrontal cortex, and the anterior insular cortex. 8 Abnormalities in central serotonergic, noradrenergic, and dopaminergic function may also be involved in IA. 9, 10 In addition, IA has been associated with dopamine hyperactivity as a result of deficient serotonergic functioning and regulation of the dopamine system in brain regions such as the nucleus accumbens and prefrontal cortex, which are linked to reward-related motivation. 12,13 Through alternative splicing, two isoforms of the D 2 receptors are generated, D 2S (short) and D 2L (long), which include 29 additional amino acids in the third intracellular loop. 12, 13 The D 2 receptors are known targets of antipsychotic drugs. 12, 13 Serotonergic neurons originate from the raphe nuclei and relay information using various neural pathways and serotonin receptors.
14 Seven serotonin receptors have been identified to date: 5-HT 1 through to 5-HT 7 .
14 The role of serotonin in IA is not completely understood, although low levels of serotonin have been associated with IA. 11 The activation or antagonism of some of the serotonin receptors has been shown to inhibit aggressive behavior, while that of others increases this behavior. [14] [15] [16] Although it is not yet completely known how SPN-810 (extended-release molindone) reduces IA, previous receptor binding studies have shown that molindone does indeed block the D 2 receptors. 17 This current manuscript will discuss in vitro pharmacological studies and elucidate the effect of molindone (SPN-810M) on the dopamine and serotonin receptors that have been implicated in IA. 20 Briefly, test compounds were preincubated with the membranes (D 2S : 0.05 mg/mL; D 2L : 0.1 mg/ mL) and GDP (guanosine 5′-diphosphate) (D 2S : 3 µM; D 2L : 10 µM) in modified HEPES buffer (20 mM HEPES, pH 7.4; 100 mM NaCl; 10 mM MgC1 2 ; 1 mM EDTA; 1 mM DTT) for 20 minutes and scintillation proximity assay beads were then added for another 60 minutes at 30°C. The reaction was initiated by 0.3 nM [ impedance measurement and cellular dielectric spectroscopy
Materials and methods compounds tested
To evaluate the antagonist activity of SPN-810M at the human D 2S receptor expressed in transfected HEK-293 cells, the CellKey (cellular dielectric spectroscopy) detection method was used to measure effects of the compound on impedance modulation. Cells were seeded onto 96-well plates coated with fibronectin at 2×10 5 cells/well in HBSS buffer + 20 mM HEPES (Thermo Fisher Scientific, Waltham, MA, USA) with 0.1% BSA and equilibrated for 45 minutes at 28°C. Plates were placed onto the system and measurements were made at 28°C. HBSS (basal and stimulated controls), reference antagonist (IC 50 determination), or the test compounds were preincubated for 15 minutes before the addition of HBSS (basal control) or the reference agonist dopamine at 30 nM (EC 80 ). Impedance measurements were monitored for 10 minutes. The standard reference antagonist butaclamol was tested in each experiment at several concentrations to generate a concentration-response curve from which its IC 50 value was calculated. Assays were run in duplicate. The analysis of other receptors (eg, 5-HT 1A ) used similar assay methods. used similar assay methods. Measurements were performed at the excitation wavelength of 337 nm, and the emission wavelength of 620 nm (donor) and 665 nm (acceptor). The HTRF ratio was calculated by dividing the acceptor signal (665 nm) by the donor signal (620 nm), which normalizes the signal and corrects the results for effects due to the optical characteristics of the media and assay components. human metabolites of sPn-810M
The major human metabolites of SPN-810M, P1-2 and P3-2, were evaluated for antagonistic effects on the dopamine and serotonin receptors. The binding assays identified no binding affinity for P1-2 on the tested receptors. Although the metabolite P3-2 had a slight antagonist effect on 5-HT 2B at concentrations greater than 10 µM, the phosphoinositide hydrolysis functional assay demonstrated an antagonist effect only at 100 µM. Additional binding assays revealed that the SPN-810M metabolites P1-2 and P3-2 did not bind to other neurotransmitter receptors, such as norepinephrine, GABA, glutamate, histamine, or acetylcholine receptors.
Potential effect of dopamine and norepinephrine on the in vitro pharmacology profile of SPN-810M antagonistic activity of SPN-810M was unaffected by the presence of 0.1 µM dopamine or norepinephrine ( Table 1) . The antagonist effect of SPN-810M on the D 2L receptor was also unaffected by the presence of norepinephrine at concentrations tested (0.1 µM, 1 µM, and 10 µM), with an IC 50 ranging from 0.05 µM to 0.11 µM (Table 1) . Likewise, the antagonist effect of SPN-810M on 5-HT 2B was not affected in the presence of dopamine or norepinephrine (IC 50 ranging from 0.19 µM to 0.45 µM; Table 1 
sPn-810M enantiomers: r(−) enantiomer vs s(+) enantiomer
Results from the [ (Table 2) . Further experiments demonstrate that the R(−) enantiomer also has a greater inhibitory effect than the S(+) enantiomer for the 5-HT 2B receptor (IC 50 =0.2 µM vs 1.8 µM, respectively; Table 2 ). insight regarding the potential mechanism, suggesting it does so mainly by modulating dopamine and also serotonin.
sPn-810M: a potent antagonist for D 2s , D 2l , and 5-hT 2B
Molindone has been found to be a potent antagonist for D 2 receptors. 17 Gene expression profiling has demonstrated that 
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Yu and gopalakrishnan molindone's effect on lipid metabolism is markedly weaker than that of the antipsychotics clozapine and risperidone. 17, 23 Molindone does not act like antipsychotics such as haloperidol, as it has been shown to elicit little to no parkinsonism or extrapyramidal symptoms and has a low propensity for weight gain. 24, 25 The results of the current radioligand binding assays and functional activity studies extend these findings and identify SPN-810M as an antagonist for D 2S , D 2L , and 5-HT 2B . SPN-810M also demonstrated an inhibitory effect on the D 1 , D 3 , D 5 , and 5-HT 2A receptors, but to a much lesser degree. The majority of atypical antipsychotics have a high affinity for 5-HT 2A , 26 although amisulpride is an example of a highly effective atypical antipsychotic that does not occupy any 5-HT 2A receptors. 27 In any case, the lack of 5-HT 2A potency suggests that SPN-810M does not act like known atypical antipsychotic drugs (with a high affinity for 5-HT 2A ). 26 Overall, these in vitro results suggest that SPN-810M at clinically relevant doses is pharmacologically distinct from both typical and atypical antipsychotic drugs, with the exception of amisulpride.
Previous studies have shown that single enantiomers and their racemates can be equipotent in in vitro and in vivo pharmacological tests 28 or that each enantiomer can have a different potency, as seen with the dopamine D 1 -like receptor partial agonist SKF 83959 enantiomer R(+) and the S(−) enantiomers, MCL 202 and MCL 201, respectively. 29 Results from the present study investigating the differential effects of the enantiomers of SPN-810M show that the racemic molecule and the R(−) enantiomer did not demonstrate significant differences in their in vitro action. However, the R(−) form showed ~100, 300, and eight times more potency as an antagonist for D 2S , D 2L , and 5-HT 2B receptors, respectively, than the S(+) enantiomer. The fact that the potency was similar for the R(−) enantiomer on D 2S and D 2L at 0.048 µM and 0.021 µM, respectively, suggests that the SPN-810M R(−) enantiomer could play a role in the D 2 autoreceptor of the dopaminergic system. In particular, SPN-810M may affect both the presynaptic D 2S autoreceptors and the postsynaptic D 2L receptors. 12, 13 Active metabolites of certain drugs, such as triptans, can induce CNS side effects by binding to 5-HT or other receptors. 30 The major human metabolites (P1-2 and P3-2) of SPN-810M did not display antagonistic effects on the dopamine or serotonin receptors in vitro. Furthermore, the metabolites did not demonstrate an inhibitory effect on several other neurotransmitter receptors tested, such as norepinephrine, GABA, glutamate, histamine, or acetylcholine receptors. This finding is in agreement with a study conducted by Balsara et al, which concluded that a molindone metabolite does not exert neuroleptic activity. 31 The lack of an effect due to the SPN-810M metabolites suggests that SPN-810M is not likely to have metabolite-related CNS side effects, improving the tolerability in a clinical setting.
The effect of psychostimulants on sPn-810M antagonism of D 2s , D 2l , and 5-hT 2B
Psychostimulants are considered first-line pharmacotherapy for the treatment of ADHD and refractory aggression, and they usually improve ADHD symptoms as well as aggressive behaviors by increasing synaptic dopamine levels in the brain. [32] [33] [34] [35] Other pharmacotherapies for ADHD include norepinephrine reuptake inhibitors. 4 However, IA symptoms that are present prior to treatment persist in ~44% of children with ADHD, despite ADHD therapy. 1, 36 Studies suggest that IA may respond to adjunctive treatments administered with optimized first-line pharmacotherapy for ADHD. 1, 37 As such, the additional assays described above were carried out to determine the effect of dopamine or norepinephrine on D 2S , D 2L , and 5-HT 2B in the presence of SPN-810M. Specifically, we wanted to evaluate whether these neurotransmitters 1) increased or decreased the antagonistic effect of SPN-810M, and/or 2) caused a reversal in function of SPN-810M from an antagonist to an agonist. The results from the in vitro pharmacology studies demonstrate that the antagonist effects of SPN-810M on the D 2S , D 2L , and 5-HT 2B receptors were not altered by the presence of dopamine or norepinephrine, as very little change in potency was observed. Furthermore, the presence of dopamine or norepinephrine did not lead to SPN-810M reversing from an antagonistic to an agonistic effect.
Theorized mechanism of action
Our in vitro assays provide some insight into the potential mechanisms of SPN-810M. The results of the in vitro pharmacology studies indicate that SPN-810M is a potent antagonist for D 2S , D 2L , and 5-HT 2B . In children (aged 6-12 years) diagnosed with ADHD and presenting with IA, SPN-810 (extended-release molindone) use at doses up to 36 mg/day resulted in significant improvements in aggressive behavior based on the Retrospective-Modified Overt Aggression Scale (R-MOAS). 21, 22 The exact mechanism of action by which SPN-810 improved aggressive behavior is not completely understood. We hypothesize that by acting as a 5-HT 2B receptor antagonist, SPN-810M can influence the mesoaccumbens dopamine pathway by reducing the outflow of dopamine. 38 Although we found that SPN-810M is an antagonist for 5-HT 2B may affect the presynaptic D 2S autoreceptors to adequately regulate the synthesis and release of dopamine into the synaptic cleft and block the postsynaptic D 2L receptors to reduce phasic DA signaling in regions of the brain that are likely to be associated with aggression. 12, 13, 39 At therapeutic doses, antagonistic effects of SPN-810M for D 2S and D 2L , as well as for 5-HT 2B , may work in concert to synergistically contribute to the clinical effects. Indeed, further in vivo neuropharmacological studies including fMRI studies may enable better understanding of the mechanism of action of this drug, with the goal of improving care for patients with IA.
